Tonghua Dongbao

Tonghua Dongbao Pharmaceutical Co., Ltd. was established in 1985, and is the earliest listed pharmaceutical company in the pharmaceutical sector of the Shanghai Stock Exchange in China. Its current total market value is 40 billion RMB. Since the 1990s, the company has been committed to the research and development and production of high-end biological drugs. Currently, it has become a leading enterprise in the field of recombinant biological products in China, especially in the production of genetically recombinant human insulin. The company has branches in Germany, Switzerland, Malaysia, and in Changchun, Beijing, Shanghai, and Xiamen in China. With an innovative R&D concept, advanced production facilities, strict quality control systems, efficient market strategies, and a comprehensive after-sales service network, the company has formed a well-organized and sustainable development operation system. Adhering to high-quality and international production standards, all insulin products of Dongbao currently meet EU and US standards. In 2013, the insulin API passed the EU GMP certification, and the insulin products have completed registration in more than 40 countries, with exports to over 20 countries. To meet the diagnostic and therapeutic needs of patients with diabetes in primary care, Dongbao, together with professional societies, has been conducting various forms of training for primary care physicians for 8 consecutive years, making significant contributions to improving the diagnostic and therapeutic level of primary care diabetes doctors in China. Dongbao is not only far ahead in the biopharmaceutical field but also keeps pace with the times in the Internet Plus aspect, having established a chronic disease management platform for diabetes. At present, through the Shulin series of insulin products, insulin injection products, blood glucose monitoring products, the 'Your Doctor' chronic disease management platform, and the after-sales service platform, Dongbao has become the first innovative biopharmaceutical company to provide integrated insulin therapy solutions for diabetic patients.